Anti-angiogenic therapy can not only normalize aberrant tumor blood vessels to improve intratumoral immune effector cell infiltration, but also reverse the immunosuppressive microenvironment induced by angiogenic inducers, especially vascular endothelial growth factor (VEGF), providing rational for the combination of anti-angiogenic therapies with immune checkpoint blockade6–8. The gene discussed is VEGFA; the disease is neoplasm.